This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Clear Cell Renal Carcinoma
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.

Provided treatments

  • Drug: Axitinib
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01599754. The sponsor of the trial is SFJ Pharma Ltd. II and it is looking for 722 volunteers for the current phase.
Official trial title:
Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC